The Trump administration has launched an investigation into Germany's pharmaceutical pricing policies, arguing that the country's pricing system may contribute to higher prescription drug costs for American consumers while affecting U.S. pharmaceutical innovation, as reported by Fox News.

The investigation was announced June 18 by U.S. Trade Representative Jamieson Greer through a Section 301 inquiry into what the administration describes as Germany's "persistent underpayment for innovative pharmaceutical products."

The review is expected to continue through the fall, with a public hearing scheduled for Sept. 22.

According to the administration, the investigation will examine whether Germany's pharmaceutical pricing practices unfairly disadvantage U.S. companies and contribute to higher drug prices in the United States.

Here's What They're Not Telling You About Your Retirement

The move follows broader efforts by the Trump administration to address prescription drug costs and what it characterizes as imbalances in international pharmaceutical pricing.

Administration officials contend that Germany, along with several other European countries, requires pharmaceutical companies to sell medications at prices below those paid by American consumers.

They argue that this pricing structure shifts a greater share of research and development costs onto U.S. purchasers.

FREE Gun Law Map: Laws Don't Pause During Social Unrest

The administration points to pricing data indicating that Americans pay significantly more for certain medications than consumers in Germany.

According to the figures cited by the administration, Americans pay four times more than Germans for the most expensive drugs developed in the United States.

Administration officials also argue that developing new medicines requires substantial investment.

They cite estimates that bringing a new pharmaceutical product to market costs an average of approximately $2.7 billion, with research expenses ultimately recovered through sales.

The administration maintains that if foreign governments negotiate substantially lower prices for medicines developed by American companies, those costs are more heavily borne by U.S. consumers and the domestic market.

The Section 301 investigation will examine Germany's pharmaceutical reimbursement system and determine whether it constitutes an unreasonable or discriminatory practice affecting U.S. commerce.

If the investigation concludes that Germany's policies violate U.S. trade standards, the administration could impose tariffs or pursue other trade remedies.

German officials have expressed concern about the investigation, warning that it could co

Warning: Account balances and purchasing power no longer tell the same story. Know in 2 minutes if your retirement is working for you.